Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes.

Hertzel C. Gerstein,Naveed Sattar,Julio Rosenstock,Chinthanie Ramasundarahettige,Richard Pratley,Renato D. Lopes,Carolyn S.P. Lam,Nardev S. Khurmi,Laura Heenan,Stefano Del Prato,Leanne Dyal,Kelley R. Branch

Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes.

2021

Hertzel C. Gerstein
Naveed Sattar
Julio Rosenstock
Chinthanie Ramasundarahettige
Richard Pratley
Renato D. Lopes
Carolyn S.P. Lam
Nardev S. Khurmi
Laura Heenan
Stefano Del Prato
Leanne Dyal
Kelley R. Branch

Abstract Background Four glucagon-like peptide-1 (GLP-1) receptor agonists that are structurally similar to human GLP-1 have been shown to reduce the risk of adverse cardiovascular events among per...

Keywords:

MEDLINE
Type 2 diabetes
Medicine
Internal medicine
Diabetes mellitus
multicenter study
Randomized controlled trial
Text mining

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations